Condition
ERBB2 Mutation-Related Tumors
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown1
Enrolling By Invitation1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07122882Enrolling By Invitation
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT06185400Phase 2Not Yet Recruiting
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
NCT05847764Phase 2Unknown
Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Showing all 3 trials